Elevated expression of RAD51 is associated with tumor aggressiveness and is known to confer treatment resistance in a variety of tumors, including ovarian cancer [43], breast cancer [44], lung tumors [45], pancreatic adenocarcinomas [46], and malignant gliomas [47]. Here, RAD51 is linked to ovarian carcinoma.